Gadolinium-based contrast agents targeted to amyloid aggregates for the early diagnosis of Alzheimer's disease by MRI

European Journal of Medicinal Chemistry

Volumn 87, Issue , 2014, Pages 843-861

  Bort, Guillaume ^a   Catoen, Sarah ^b   Borderies, Hélène ^a   Kebsi, Adel ^a   Ballet, Sébastien ^b   Louin, Gaëlle ^b   Port, Marc ^a,b   Ferroud, Clotilde ^a  

^a University of Paris Cité   (France)

^b Laboratoire Guerbet   (France)

Author keywords

Alzheimer's disease; Amyloid; DOTA; Gadolinium; Magnetic resonance imaging (MRI); Pyridine containing TriAza (PCTA)

Indexed keywords

2,3 DIHYDRO 1H IMIDAZO[1,2 B]PYRAZOLE; 3,6,9,15 TETRAAZA BICYCLO[9.3.1]PENTADECA 1(15),11,13 TRIENE 3,6,9 TRIACETIC ACID; AMYLOID BETA PROTEIN; GADOLINIUM CHELATE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; RADIOLIGAND; TETRAXETAN; UNCLASSIFIED DRUG;

AGED; ALKYLATION; ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BINDING SITE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; BRAIN HOMOGENATE; COMPLEX FORMATION; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; CYCLIZATION; DEMETHYLATION; DISSOCIATION; DRUG BINDING; DRUG CONJUGATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; EARLY DIAGNOSIS; GLIA CELL; HUMAN; HUMAN TISSUE; HYDROGEN BOND; HYDROGENATION; IC50; IN VITRO STUDY; LIPOPHILICITY; MEMBRANE PERMEABILITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL CHEMISTRY; PLASMA PROTEIN BINDING; PROTEIN AGGREGATION; RADIOACTIVITY; RAT; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION; TIGHT JUNCTION; TRANSCYTOSIS;

EID: 84908446775     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.10.016     Document Type: Article

References (79)

1. N.L. Batsch, M.S. Mittelman, World Alzheimer Report 2012, Alzheimer's Disease International, London, 2012, pp. 1-80.
2. R. Brookmeyer, E. Johnson, K. Ziegler-Graham, H.M. Arrighi, Forecasting the global burden of Alzheimer's disease, Alzheimers Dement. 3 (2007) 186-191.
3. A. Nordberg, Amyloid plaque imaging in vivo: current achievement and future prospects, Eur. J. Nucl. Med. Mol. Imaging 35 (Suppl. 1) (2008) S46-S50.
4. D.M. Holtzman, J.C. Morris, A.M. Goate, Alzheimer's disease: the challenge of the second century, Sci. Transl. Med. 3 (2011) 77.
5. Y. Huang, L. Mucke, Alzheimer mechanisms and therapeutic strategies, Cell 148 (2012) 1204-1222.
6. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, E.M. Stadlan, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology 34 (1984) 939-944.
7. B. Dubois, H.H. Feldman, C. Jacova, S.T. Dekosky, P. Barberger-Gateau, J. Cummings, A. Delacourte, D. Galasko, S. Gauthier, G. Jicha, K. Meguro, J. O'Brien, F. Pasquier, P. Robert, M. Rossor, S. Salloway, Y. Stern, P.J. Visser, P. Scheltens, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet Neurol. 6 (2007) 734-746.
8. J.A. Hardy, G.A. Higgins, Alzheimer's disease: the amyloid cascade hypothesis, Science 256 (1992) 184-185.
9. A. Nordberg, Amyloid imaging in early detection of Alzheimer's disease, Neurodegener. Dis. 7 (2010) 136-138.
10. A. Nordberg, J.O. Rinne, A. Kadir, B. La˚ngström, The use of PET in Alzheimer disease, Nat. Rev. Neurol. 6 (2010) 78-87.
11. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, M.W. Weiner, R.C. Petersen, J.Q. Trojanowski, Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade, Lancet Neurol. 9 (2010) 119-128.
12. A. Nordberg, Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development, Alzheimer's Res. Ther. 3 (2011) 34.
13. L. Cai, R.B. Innis, V.W. Pike, Radioligand development for PET imaging of beta-amyloid (Abeta) - current status, Curr. Med. Chem. 14 (2007) 19-52.
14. S. Furumoto, N. Okamura, R. Iwata, K. Yanai, H. Arai, Y. Kudo, Recent advances in the development of amyloid imaging agents, Curr. Top. Med. Chem. 7 (2007) 1773-1789.
15. K.-L. Xiong, Q.-W. Yang, S.-G. Gong, W.-G. Zhang, The role of positron emission tomography imaging of [beta]-amyloid in patients with Alzheimer's disease, Nucl. Med. Commun. 31 (2010) 4-11.
16. C.M. Clark, J.A. Schneider, B.J. Bedell, T.G. Beach, W.B. Bilker, M.A. Mintun, M.J. Pontecorvo, F. Hefti, A.P. Carpenter, M.L. Flitter, M.J. Krautkramer, H.F. Kung, R.E. Coleman, P.M. Doraiswamy, A.S. Fleisher, M.N. Sabbagh, C.H. Sadowsky, E.M. Reiman, S.P. Zehntner, D.M. Skovronsky, Use of florbetapir-pet for imaging β-amyloid pathology, J. Am. Med. Assoc. 305 (2011) 275-283.
17. A. Forsberg, H. Engler, O. Almkvist, G. Blomquist, G. Hagman, A. Wall, A. Ringheim, B. La˚ngström, A. Nordberg, PET imaging of amyloid deposition in patients with mild cognitive impairment, Neurobiol. Aging 29 (2008) 1456-1465.
18. A. Okello, J. Koivunen, P. Edison, H.A. Archer, F.E. Turkheimer, K. Nagren, R. Bullock, Z. Walker, A. Kennedy, N.C. Fox, M.N. Rossor, J.O. Rinne, D.J. Brooks, Conversion of amyloid positive and negative MCI to AD over 3 years, Neurology 73 (2009) 754-760.
19. S.M. Landau, C. Breault, A.D. Joshi, M. Pontecorvo, C.A. Mathis, W.J. Jagust, M.A. Mintun, Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods, J. Nucl. Med. 54 (2013) 70-77.
20. C.C. Rowe, S. Ng, U. Ackermann, S.J. Gong, K. Pike, G. Savage, T.F. Cowie, K.L. Dickinson, P. Maruff, D. Darby, C. Smith, M. Woodward, J. Merory, H. Tochon-Danguy, G. O'Keefe, W.E. Klunk, C.A. Mathis, J.C. Price, C.L. Masters, V.L. Villemagne, Imaging beta-amyloid burden in aging and dementia, Neurology 68 (2007) 1718-1725.
21. M.A. Mintun, G.N. Larossa, Y.I. Sheline, C.S. Dence, S.Y. Lee, R.H. Mach, W.E. Klunk, C.A. Mathis, S.T. DeKosky, J.C. Morris, [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease, Neurology 67 (2006) 446-452.
22. K.E. Pike, G. Savage, V.L. Villemagne, S. Ng, S.A. Moss, P. Maruff, C.A. Mathis, W.E. Klunk, C.L. Masters, C.C. Rowe, Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease, Brain 130 (2007) 2837-2844.
23. H.J. Aizenstein, R.D. Nebes, J.A. Saxton, J.C. Price, C.A. Mathis, N.D. Tsopelas, S.K. Ziolko, J.A. James, B.E. Snitz, P.R. Houck, W. Bi, A.D. Cohen, B.J. Lopresti, S.T. DeKosky, E.M. Halligan, W.E. Klunk, Frequent amyloid deposition without significant cognitive impairment among the elderly, Arch. Neurol. 65 (2008) 1509-1517.
24. E.C. Mormino, M.G. Brandel, C.M. Madison, G.D. Rabinovici, S. Marks, S.L. Baker, W.J. Jagust, Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant, Neuroimage 59 (2012) 1152-1160.
25. J.C. Morris, C.M. Roe, E.A. Grant, D. Head, A.M. Goate, A.M. Fagan, D.M. Holtzman, M.A. Mintun, Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease, Arch. Neurol. 66 (2009) 1469-1475.
26. A.G. Vlassenko, M.A. Mintun, C. Xiong, Y.I. Sheline, A.M. Goate, T.L.S. Benzinger, J.C. Morris, Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data, Ann. Neurol. 70 (2011) 857-861.
27. J.L. Price, D.W. McKeel, V.D. Buckles, C.M. Roe, C. Xiong, M. Grundman, L.A. Hansen, R.C. Petersen, J.E. Parisi, D.W. Dickson, C.D. Smith, D.G. Davis, F.A. Schmitt, W.R. Markesbery, J. Kaye, R. Kurlan, C. Hulette, B.F. Kurland, R. Higdon, W. Kukull, J.C. Morris, Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease, Neurobiol. Aging 30 (2009) 1026-1036.
28. D.E. Huddleston, S.A. Small, Technology insight: imaging amyloid plaques in the living brain with positron emission tomography and MRI, Nat. Clin. Pract. Neuro 1 (2005) 96-105.
29. R.A. Yotter, J. Doshi, V. Clark, J. Sojkova, Y. Zhou, D.F. Wong, L. Ferrucci, S.M. Resnick, C. Davatzikos, Memory decline shows stronger associations with estimated spatial patterns of amyloid deposition progression than total amyloid burden, Neurobiol. Aging 34 (2013) 2835-2842.
30. S. Aime, C. Cabella, S. Colombatto, S. Geninatti Crich, E. Gianolio, F. Maggioni, Insights into the use of paramagnetic Gd(III) complexes in MR-molecular imaging investigations, J. Magn. Reson. Imaging 16 (2002) 394-406.
31. C. Corot, P. Robert, E. Lancelot, P. Prigent, S. Ballet, I. Guilbert, J.-S. Raynaud, I. Raynal, M. Port, Tumor imaging using P866, a high-relaxivity gadolinium chelate designed for folate receptor targeting, Magn. Reson. Med. 60 (2008) 1337-1346.
32. J. Näslund, V. Haroutunian, R. Mohs, K.L. Davis, P. Davies, P. Greengard, J.D. Buxbaum, Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline, J. Am. Med. Assoc. 283 (2000) 1571-1577.
33. C.A. Mathis, Y. Wang, D.P. Holt, G.F. Huang, M.L. Debnath, W.E. Klunk, Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents, J. Med. Chem. 46 (2003) 2740-2754.
34. A.F. Martins, J.-F. Morfin, C.F.G.C. Geraldes, É. Tóth, Gd(3+) complexes conjugated to Pittsburgh compound B: potential MRI markers of β-amyloid plaques, J. Biol. Inorg. Chem. 19 (2014) 281-295.
35. Y.Z. Wadghiri, E.M. Sigurdsson, M. Sadowski, J.I. Elliott, Y. Li, H. Scholtzova, C.Y. Tang, G. Aguinaldo, M. Pappolla, K. Duff, T. Wisniewski, D.H. Turnbull, Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging, Magn. Reson. Med. 50 (2003) 293-302.
36. J.F. Poduslo, T.M. Wengenack, G.L. Curran, T. Wisniewski, E.M. Sigurdsson, S.I. Macura, B.J. Borowski, C.R. Jack, Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging, Neurobiol. Dis. 11 (2002) 315-329.
37. J.F. Poduslo, G.L. Curran, J.A. Peterson, D.J. McCormick, A.H. Fauq, M.A. Khan, T.M. Wengenack, Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques, Biochemistry 43 (2004) 6064-6075.
38. E.M. Sigurdsson, Y.Z. Wadghiri, L. Mosconi, J.A. Blind, E. Knudsen, A. Asuni, H. Scholtzova, W.H. Tsui, Y. Li, M. Sadowski, D.H. Turnbull, M.J. del, T. Wisniewski, A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice, Neurobiol. Aging 29 (2008) 836-847.
39. A.F. Martins, J.-F. Morfin, A. Kubíčková, V. Kubíček, F. Buron, F. Suzenet, M. Salerno, A.N. Lazar, C. Duyckaerts, N. Arlicot, D. Guilloteau, C.F.G.C. Geraldes, É. Tóth, PiB-conjugated, metal-based imaging probes: Multimodal approaches for the visualization of β-amyloid plaques, ACS Med. Chem. Lett. 4 (2013) 436-440.
40. J. Yang, Y.Z. Wadghiri, D.M. Hoang, W. Tsui, Y. Sun, E. Chung, Y. Li, A. Wang, L.M. de, T. Wisniewski, Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging, Neuroimage 55 (2011) 1600-1609.
41. Y.Z. Wadghiri, J. Li, J. Wang, D.M. Hoang, Y. Sun, H. Xu, W. Tsui, Y. Li, A. Boutajangout, A. Wang, M. de Leon, T. Wisniewski, Detection of amyloid plaques targeted by bifunctional USPIO in Alzheimer's disease transgenic mice using magnetic resonance microimaging, PLoS ONE 8 (2013) e57097.
42. W.E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, D.P. Holt, M. Bergström, I. Savitcheva, G.F. Huang, S. Estrada, B. Ausen, M.L. Debnath, J. Barletta, J.C. Price, J. Sandell, B.J. Lopresti, A. Wall, P. Koivisto, G. Antoni, C.A. Mathis, B. La˚ngström, Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B, Ann. Neurol. 55 (2004) 306-319.
43. S.R. Choi, G. Golding, Z. Zhuang, W. Zhang, N. Lim, F. Hefti, T.E. Benedum, M.R. Kilbourn, D. Skovronsky, H.F. Kung, Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain, J. Nucl. Med. 50 (2009) 1887-1894.
44. N. Nelissen, K. Van Laere, L. Thurfjell, R. Owenius, M. Vandenbulcke, M. Koole, G. Bormans, D.J. Brooks, R. Vandenberghe, Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease, J. Nucl. Med. 50 (2009) 1251-1259.
45. C.C. Rowe, U. Ackerman, W. Browne, R. Mulligan, K.L. Pike, G. O'Keefe, H. Tochon-Danguy, G. Chan, S.U. Berlangieri, G. Jones, K.L. Dickinson-Rowe, H.P. Kung, W. Zhang, M.P. Kung, D. Skovronsky, T. Dyrks, G. Holl, S. Krause, M. Friebe, L. Lehman, S. Lindemann, L.M. Dinkelborg, C.L. Masters, V.L. Villemagne, Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism, Lancet Neurol. 7 (2008) 129-135.
46. 11C]AZD2184, Eur. J. Nucl. Med. Mol. Imaging 36 (2009) 1859-1863.
47. Y. Gravenfors, C. Jonasson, J. Malmstroem, G. Nordvall, D. Pyring, C. Slivo, D. Sohn, P. Stroem, D. Wensbo, Preparation of Heteroarylbenzothiazoles for Imaging of Amyloid deposits and treatment of Alzheimer's disease, WO 2007086800.
48. T. Kato, K. Ito, K. Hatano, A. Nakamura, N. Okamura, K. Yanai, [C-11]BF-227 PET imaging of amyloid deposition in AD, MCI, and normal subjects, J. Nucl. Med. 50 (Suppl. 2) (2009) 426.
49. G.D. Rabinovici, W.J. Jagust, Amyloid imaging in aging and dementia: Testing the amyloid hypothesis in vivo, Behav. Neurol. 21 (2009) 117-128.
50. W.E. Klunk, C.A. Mathis, The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation, Curr. Opin. Neurol. 21 (2008) 683-687.
51. Z.-P. Zhuang, M.-P. Kung, C. Hou, K. Plossl, D. Skovronsky, T.L. Gur, J.Q. Trojanowski, V.M.Y. Lee, H.F. Kung, IBOX (2-(4′-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain, Nucl. Med. Biol. 28 (2001) 887-894.
52. M.-P. Kung, C. Hou, Z.-P. Zhuang, D. Skovronsky, H.F. Kung, Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease, Brain Res. 1025 (2004) 98-105.
53. H.F. Kung, C.-W. Lee, Z.-P. Zhuang, M.-P. Kung, C. Hou, K. Ploessl, Novel stilbenes as probes for amyloid plaques, J. Am. Chem. Soc. 123 (2001) 12740-12741.
54. 11C]SB-13 PET, Am. J. Geriat. Psychiatry 12 (2004) 584-595.
55. R. Leuma Yona, S. Mazeres, P. Faller, E. Gras, Thioflavin derivatives as markers for amyloid-beta fibrils: insights into structural features important for high-affinity binding, ChemMedChem 3 (2008) 63-66.
56. X. Chen, QSAR and primary docking studies of trans-stilbene (TSB) series of imaging agents for beta-amyloid plaques, J. Mol. Struct. THEOCHEM 763 (2006) 83-89.
57. Z.-P. Zhuang, M.-P. Kung, C. Hou, K. Ploessl, H.F. Kung, Biphenyls labeled with technetium 99m for imaging beta-amyloid plaques in the brain, Nucl. Med. Biol. 32 (2005) 171-184.
58. X. Chen, P. Yu, L. Zhang, B. Liu, Synthesis and biological evaluation of 99mTc, Re-monoamine-monoamide conjugated to 2-(4-aminophenyl)benzothiazole as potential probes for beta-amyloid plaques in the brain, Bioorg. Med. Chem. Lett. 18 (2008) 1442-1445.
59. M. Ono, R. Ikeoka, H. Watanabe, H. Kimura, T. Fuchigami, M. Haratake, H. Saji, M. Nakayama, Synthesis and evaluation of novel chalcone derivatives with 88mTc/Re complexes as potential probes for detection of beta-amyloid plaques, ACS Chem. Neurosci. 1 (2010) 598-607.
60. P. Caravan, J.J. Ellison, T.J. McMurry, R.B. Lauffer, Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications, Chem. Rev. 99 (1999) 2293-2352.
61. S. Aime, M. Botta, S. Geninatti Crich, G.B. Giovenzana, G. Jommi, R. Pagliarin, M. Sisti, Synthesis and NMR studies of three pyridine-containing Triaza macrocyclic Triacetate ligands and their complexes with lanthanide ions, Inorg. Chem. 36 (1997) 2992-3000.
62. J.-M. Idee, M. Port, C. Medina, E. Lancelot, E. Fayoux, S. Ballet, C. Corot, Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review, Toxicology 248 (2008) 77-88.
63. C. Ferroud, H. Borderies, E. Lasri, A. Guy, M. Port, Synthesis of a novel amphiphilic GdPCTA-[12] derivative as a potential micellar MRI contrast agent, Tetrahedron Lett. 49 (2008) 5972-5975.
64. K.P. Eisenwiener, P. Powell, H.R. Mäcke, A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling, Bioorg. Med. Chem. Lett. 10 (2000) 2133-2135.
65. D.F. Shi, T.D. Bradshaw, S. Wrigley, C.J. McCall, P. Lelieveld, I. Fichtner, M.F. Stevens, Antitumor benzothiazoles. 3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo, J. Med. Chem. 39 (1996) 3375-3384.
66. G. Bort, M. Sylla-Iyarreta Veitia, C. Ferroud, Straightforward synthesis of PET tracer precursors used for the early diagnosis of Alzheimer's disease through Suzuki-Miyaura cross-coupling reactions, Tetrahedron 69 (2013) 7345-7353.
67. W. Zhang, S. Oya, M.P. Kung, C. Hou, D.L. Maier, H.F. Kung, F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain, J. Med. Chem. 48 (2005) 5980-5988.
68. A. Benarab, S. Boye, L. Savelon, G. Guillaumet, Use of the cyanomethyl group as protecting group for phenols, amines and carbamates, Tetrahedron Lett. 34 (1993) 7567-7568.
69. H.C. Brown, Y.M. Choi, S. Narasimhan, Selective reductions. 29. A simple technique to achieve an enhanced rate of reduction of representative organic compounds by borane-dimethyl sulfide, J. Org. Chem. 47 (1982) 3153-3163.
70. A. Romieu, D. Brossard, M. Hamon, H. Outaabout, C. Portal, P.-Y. Renard, Postsynthetic derivatization of fluorophores with alpha-sulfo-beta-alanine dipeptide linker. Application to the preparation of water-soluble cyanine and rhodamine dyes, Bioconjug. Chem. 19 (2008) 279-289.
71. S.L. Niu, G. Ulrich, R. Ziessel, A. Kiss, P.-Y. Renard, A. Romieu, Water-soluble BODIPY derivatives, Org. Lett. 11 (2009) 2049-2052.
72. A. Lockhart, L. Ye, D.B. Judd, A.T. Merritt, P.N. Lowe, J.L. Morgenstern, G. Hong, A.D. Gee, J. Brown, Evidence for the presence of three distinct binding sites for the thioflavin t class of Alzheimer's disease PET imaging agents on β-amyloid peptide fibrils, J. Biol. Chem. 280 (2005) 7677-7684.
73. S. Aime, M. Botta, S.G. Crich, G. Giovenzana, R. Pagliarin, M. Sisti, E. Terreno, NMR relaxometric studies of Gd(III) complexes with heptadentate macrocyclic ligands, Magn. Reson. Chem. 36 (1998) S200-S208.
74. G.M. Nicolle, E. Tóth, K.-P. Eisenwiener, H.R. Mäcke, A.E. Merbach, From monomers to micelles: investigation of the parameters influencing proton relaxivity, J. Biol. Inorg. Chem. 7 (2002) 757-769.
75. P. Caravan, Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action, Acc. Chem. Res. 42 (2009) 851-862.
76. B. Milton W, Morphology of blood-brain interfaces, Exp. Eye Res. 25 (1977) 1-25.
77. F. Herve, N. Ghinea, J.-M. Scherrmann, CNS delivery via adsorptive transcytosis, AAPS J. 10 (2008) 455-472.
78. S. Lundquist, M. Renftel, The use of in vitro cell culture models for mechanistic studies and as permeability screens for the blood-brain barrier in the pharmaceutical industry - background and current status in the drug discovery process, Vasc. Pharmacol. 38 (2002) 355-364.
79. A. Reichel, D. Begley, N.J. Abbott, An overview of in vitro techniques for blood-brain barrier studies, in: S. Nag (Ed.), The Blood-brain Barrier, vol. 89, Humana Press, Toronto, 2003, pp. 307-324.